Zenas BioPharma Prices $300M Concurrent Offering to Fund Drug Launch and Pipeline
ZBIO has more than doubled off its 52-week low of $6.11 on light trading volume (0.3× avg).
Summary
Zenas BioPharma has priced its concurrent public offerings, securing $200 million from convertible senior notes and $100 million from common stock, totaling $300 million in gross proceeds. The common stock was priced at $20.00 per share, while the convertible notes feature an initial conversion price of $26.50, a 32.5% premium. This financing follows the company's recent announcement of proposed offerings and comes after positive Phase 3 results for obexelimab, alongside a 10-K filing that noted significant losses and a going concern warning. The $287.5 million in net proceeds is a material capital infusion, crucial for funding the planned U.S. commercial launch of obexelimab, if approved, and advancing its development pipeline. Investors will now watch for the closing of these offerings on March 31, 2026, and the subsequent progress in commercialization and pipeline development.
At the time of this announcement, ZBIO was trading at $20.05 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.3B. The 52-week trading range was $6.11 to $44.60. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.